Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
OLOlema Pharmaceuticals, Inc. logo

Olema Pharmaceuticals, Inc. (OLMA)

NASDAQ Global Select · Currency in USD
$6.41 ▼ -0.61 (-8.69%)
At close: Oct 23, 4:00 PM ET. Market closed.
$6.52 ▲ +0.11 (+1.72%)
After hours: Oct 23, 7:54 PM ET

Summary

Previous Close
$7.02
Open
$6.93
Day's Range
$6.24 – $7.02
52 Week Range
$6.24 – $36.26
Volume
1,984,562
Avg. Volume
1,286,822
Market Cap
$560.86M
Beta (5Y Monthly)
2.01
PE Ratio (TTM)
--
EPS (TTM)
-$1.96
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$28.33

Profile: Olema Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
150
CEO
Sean Bohen
Website
olema.com

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.60 · Revenue est. $1.25M
DateEst.Actual
Aug 10, 2026-$0.55-$0.61Miss
May 12, 2026-$0.52-$0.52Beat
Mar 16, 2026-$0.51-$0.50Beat
Nov 10, 2025-$0.44-$0.49Miss
Aug 11, 2025-$0.43-$0.51Miss
May 13, 2025-$0.49-$0.36Beat

Analyst view

Consensus price target
$28.33 ▲ +342.0%
Range $20.00 – $35.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Similar stocks

Get free alerts on OLMA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.